CLL-984: CLL18/MOIRAI International Phase 3 Trial: Aiming to Establish Measurement of Individual Residual Disease for Adjustment of Treatment Duration to Improve Outcomes in First-Line Treatment of CLL/SLL
Léa Mazot, Ellinor Görgen, Sandra Robrecht, Antonia Albrecht et autres